Metabolic Disorders in Patients with Drug-Induced Hypogonadism

1 United Nations Department of Economic and Social Affairs: Leaving No One Behind in an Ageing World, Jan 2023; DOI:10.18356/9789210019682. Search in Google Scholar

2 EAU Guidelines. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3. Search in Google Scholar

3 Choi E, Buie J, Camacho J, et al. Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers. Res Rep Urol. 2022 Mar 30;14:87-108. Search in Google Scholar

4 Ritch C, Cookson M. Recent trends in the management of advanced prostate cancer. F1000Res. 2018 Sep 21;7:F1000 Faculty Rev-1513. doi: 10.12688/f1000research.15382.1 Search in Google Scholar

5 Frydenberg M, Woo HH. Early Androgen Deprivation Therapy Improves Survival, But How Do We Determine in Whom? Eur Urol. 2018 Apr;73(4):519-520. doi: 10.1016/j.eururo.2018.01.004. Search in Google Scholar

6 Liede A, Hallett DC, Hope K, et al. International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries. ESMO Open. 2016 Mar 18;1(2):e000040. Search in Google Scholar

7 Agrawal V, Ma X, Hu JC, et al. Trends in Androgen Deprivation Use in Men With Intermediate-Risk Prostate Cancer Who Underwent Radiation Therapy. Adv Radiat Oncol. 2022 Feb 4;7(4):100904. Search in Google Scholar

8 Haffner SM, Shaten J, Stern MP, et al. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996 May 1;143(9):889-97. Search in Google Scholar

9 Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA. 1982 Sep 24;248(12):1465-77. Search in Google Scholar

10 Muller M, Grobbee DE, den Tonkelaar I, et al. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab. 2005 May;90(5):2618-23. doi: 10.1210/jc.2004-1158. Search in Google Scholar

11 Shahinian VB, Kuo YF, Freeman JL, et al. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005 Apr 15;103(8):1615-24. doi: 10.1002/cncr.20955 Search in Google Scholar

12 Satariano WA, Ragland KE, Van Den Eeden SK. Cause of death in men diagnosed with prostate carcinoma. Cancer. 1998 Sep 15;83(6):1180-8. Search in Google Scholar

13 Mangiola S, Stuchbery R, McCoy P, et al. Androgen deprivation therapy promotes an obesity-like microenvironment in periprostatic fat. Endocr Connect. 2019 May 1;8(5):547-558. doi: 10.1530/EC-19-0029. Search in Google Scholar

14 Boban M. Cardiovascular diseases and androgen deprivation therapy. Acta Clin Croat 2019; Nov;58(Suppl 2):60-63. doi: 10.20471/acc.2019.58.s2.09. Search in Google Scholar

15 Basaria S, Lieb 2nd J, Tang A, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002; 56:77 –786 Search in Google Scholar

16 Bhasin S, Taylor WE, Singh R, et al. The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action. J Gerontol A Biol Sci Med Sci 2003;58:M1103-10. Search in Google Scholar

17 Herbst KL, Bhasin S. Testosterone action on skeletal muscle. Curr Opin Clin Nutr Metab Care 2004;7:271-7. Search in Google Scholar

18 Basaria S, Wahlstrom JT, Dobs AS. Anabolic-androgenic steroid therapy in the treatment of chronic diseases. J Clin Endocrinol Metab 2001; 86:5108–5117. Search in Google Scholar

19 Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001; 86:426–4267. Search in Google Scholar

20 Smith MR, Finkelstein JS, McGovern FJ et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J. Clin. Endocrinol. Metab. 2002; 87: 599–603/ Search in Google Scholar

21 Maillefert JF, Sibilia J, Michel F et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J. Urol. 1999; 161: 1219–22. Search in Google Scholar

22 Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 2004; 63: 742–5. Search in Google Scholar

23 Kassi E, Pervanidou P, Kaltsas G, et al. Metabolic syndrome: definitions and controversies. BMC Med 2011, 9, 48. Search in Google Scholar

24 Gleicher S, Daugherty M, Ferry E, et al. Looking beyond hypogonadism: association between low testosterone and metabolic syndrome in men 20–59 years. Int Urol Nephrol, 2020, 52, 2237–2244. Search in Google Scholar

25 Muller M, Grobbee DE, den Tonkelaar I, et al. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005; 90:2618 –2623. Search in Google Scholar

26 Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing longterm androgen-deprivation therapy. J Clin Oncol. 2006 Aug 20;24(24):3979–83. Search in Google Scholar

27 CS Massaro JM, Hoffmann U, Pou KM, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007 Jul 3;116(1):39–48. Search in Google Scholar

28 Haffner SM, Valdez RA, Mykkanen L, et al. Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism 1994; 43:599–603 22. Search in Google Scholar

29 Laaksonen DE, Niskanen L, Punnonen K, et al.Testosterone and sex hormonebinding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27:1036–1041. Search in Google Scholar

30 Tsai EC, Matsumoto AM, Fujimoto WY, et al. Association of bioavailable, free, and total testosterone with insulin resistance. Diabetes Care 2004; 27:861–8. Search in Google Scholar

31 Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005 Sep;63(3):280-93. Search in Google Scholar

32 Kumar S, Khatri M, Memon RA, et al. Effects of testosterone therapy in adult males with hypogonadism and T2DM: A meta-analysis and systematic review. Diabetes Metab Syndr. 2022 Aug;16(8):102588. Search in Google Scholar

33 Basaria S, Muller DC, Carducci MA, et al. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen deprivation therapy. Cancer 2006; 106:581–588. Search in Google Scholar

34 Pyorala M, Miettinen H, Laakso M, et al. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation. 1998 Aug 4;98(5):398–404. Search in Google Scholar

35 Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. The New England journal of medicine. 1996 Apr 11;334(15):952–7. Search in Google Scholar

36 Keating NL, O’Malley AJ, Freedland SJ et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst, 2010. 102: 39. Search in Google Scholar

37 Garnick MB, Pratt CM, Campion M, et al. The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix. J Clin Oncol 2004; 22:4578. Search in Google Scholar

38 Bosco C, Bosnyak Z, Malmberg A, et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol, 2015. 68: 386. Search in Google Scholar

39 Tsai HK, D’Amico AV, Sadetsky N, et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst, 2007. 99: 1516. Search in Google Scholar

40 Nguyen PL, Chen MH, Beckman JA et al. Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys, 2012. 82: 1411. Search in Google Scholar

41 Lopes RD, Higano CS, Slovin SF et al. Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. Circulation, 2021. 144: 1295. Search in Google Scholar

42 Tisseverasinghe S, Tolba M, Saad F et al. Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists? J Clin Oncol, 2022. 40: 4173. Search in Google Scholar

43 Shore ND, Saad F, Cookson MS, et al. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med, 2020. 382: 2187. Search in Google Scholar

44 Brookman-May SD, Campi R, Henríquez JDS et al. Latest Evidence on the Impact of Smoking, Sports, and Sexual Activity as Modifiable Lifestyle Risk Factors for Prostate Cancer Incidence, Recurrence, and Progression: A Systematic Review of the Literature by the European Association of Urology Section of Oncological Urology (ESOU). Eur Urol Focus, 2019. 5:756. Search in Google Scholar

45 Gilbert SE, Tew GA, Fairhurst C, et al. Effects of a lifestyle intervention on endothelial function in men on long-term androgen deprivation therapy for prostate cancer. Br J Cancer, 2016. 114: 401. Search in Google Scholar

46 Nobes JP, Langley SE, Klopper T, et al. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int, 2012. 109: 1495. Search in Google Scholar